• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

TABLE 137Outputs from the PenTAG and Eisai/Pfizer models for donepezil (moderate cohort)a

OutputTreatmentModel outputsIncremental values
Eisai/PfizerPenTAGEisai/PfizerPenTAG
ICERDonepezil dominatesDonepezil dominates
Total costs (£)Donepezil102,08666,896
No treatment103,96967,517−1883−621
Total QALYsDonepezil4.353 (patient + carer)b1.535
No treatment4.245 (patient + carer)b1.5000.1080.035
Undiscounted total life-years4.6033.633
Undiscounted life-years in communityDonepezil1.8522.418
No treatment1.6852.2760.1670.142
Undiscounted years in institutional careDonepezil2.7511.215
No treatment2.9181.357−0.167−0.142
Mean treatment duration (years)1.890.67
Total drug costs (£)1973780
Total monitoring costs (£)Donepezil208212
No treatment00208212
Total pre-inst costs (£)Donepezil39,20140,135
No treatment37,41338,69017881445
Total inst costs (£)Donepezil60,70525,769
No treatment66,55628,8275851−3058

Inst, institutionalisation.

a

All costs and QALYs discounted.

b

Eisai/Pfizer base case includes carer QALYs, therefore total QALYs=patient QALYs+carer QALYs. Donepezil total QALYs=1.332+3.021; no-treatment total QALYS=1.234+3.011.

All costs and QALYs discounted.

Eisai/Pfizer base case includes carer QALYs, therefore total QALYs=patient QALYs+carer QALYs. Donepezil total QALYs=1.332+3.021; no-treatment total QALYS=1.234+3.011.

From: 6, The Peninsula Technology Assessment Group cost–utility assessment

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.